Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sunao Manabe, DVM, PhD, will continue to serve as representative director and ...

Daiichi Sankyo promoted Hiroyuki Okuzawa as CEO, succeeding Sunao Manabe, DVM, PhD on April 1, 2025. Astellas’ chief commercial officer Claus Zieler is set to take up the new role of chief commercial ...

A court ruling that went against the government started a “20-year gap” in vaccine development that has come back to haunt Japan. Japan is lagging far behind the rest of the developed world in ...

TOKYO, January 31, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

Mr. Okuzawa who currently serves as Representative Director, President, and COO, will succeed Sunao Manabe, who will continue to serve as Representative Director and Executive Chairperson.

Veteran scientist Hideo Makimura, M.D., Ph.D., is going fully preclinical by joining gene therapy biotech Affinia Therapeutics as chief medical officer. Makimura most recently served in leadership ...

*Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

US Bancorp has announced that its current president, Gunjan Kedia, will assume the role of CEO on April 15, succeeding company chairman and CEO Andy Cecere. Kedia, who joined US Bancorp in 2016, has ...